Radium-223 chloride - Bayer HealthCare

Drug Profile

Radium-223 chloride - Bayer HealthCare

Alternative Names: AC1O4D1M; Alpharadin; ATI-BC-1; BAY88-8223; Radium Ra 233 dichloride; Radium-223; Radium-223 dichloride; Xofigo

Latest Information Update: 03 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Algeta
  • Developer Algeta; Bayer HealthCare; Janssen; Medica Scientia Innovation Research; Sheffield Teaching Hospitals NHS Foundation Trust; Thomas Jefferson University; University of Texas M. D. Anderson Cancer Center; University of Utah
  • Class Antineoplastics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bone metastases
  • Phase II Prostate cancer
  • Phase I/II Multiple myeloma
  • No development reported Osteosarcoma
  • Discontinued Cancer pain

Most Recent Events

  • 31 Aug 2018 Bayer completes a phase I/II trial in Bone metastases (Combination therapy, Late-stage disease, Second-line therapy or greater) in United Kingdom (IV) (ISRCTN92755158)
  • 27 Aug 2018 Committee for Medicinal Products for Human Use (CHMP) endorse recommendations from the Pharmacovigilance Risk Assessment Committee (PRAC) to restrict use of radium-223 chloride for prostate cancer with the bone metastasis to patients who had two previous treatments
  • 27 Aug 2018 Efficacy data from the phase III ERA-223 trial in Bone metastasis released by the European Medicines Agency (EMA)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top